ArticleBlood advances2017
Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Laboratory Assessment and Clinical Outlook forAnnals of laboratory medicine · 2026Review
- Novel Thrombopoietin-Mimetic Peptide 2B9F: A Promising Therapeutic Candidate for Hematopoietic Acute Radiation Syndrome.ACS omega · 2026Article
- Mass production of iPSC-derived platelets toward the clinical application.Regenerative therapy · 2024Review
- Article
- Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets.International journal of hematology · 2023Review
- Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial.Blood advances · 2022Article
- Review
- Generation and manipulation of human iPSC-derived platelets.Cellular and molecular life sciences : CMLS · 2021Review
- Development of platelet replacement therapy using human induced pluripotent stem cells.Development, growth & differentiation · 2021Review
- miR-125a-5p regulates megakaryocyte proplatelet formation via the actin-bundling protein L-plastin.Blood · 2020Article
- A β1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production.Blood advances · 2018Article
- Thrombopoietin knock-in augments platelet generation from human embryonic stem cells.Stem cell research & therapy · 2018Article
- HumanBlood · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signaling by thrombopoietin (TPO) in complex with its receptor, c-MPL, is critical for hematopoietic stem cell (HSC) homeostasis and platelet generation. Here we show that TA-316, a novel chemically synthesized c-MPL agonist (CMA), is useful for ex vivo platelet generation from human-induced pluripotent stem (iPS) cell-derived immortalized megakaryocyte progenitor cell lines (imMKCLs). Moreover, the generation is clinically applicable, because self-renewal expansion and platelet release is tightly controllable. TA-316 but not eltrombopag, another CMA, promoted both the self-renewal and maturation of imMKCLs, leading to more than a twofold higher platelet production than that achieved with recombinant human TPO (rhTPO). Interestingly, TA-316 seemed to favor MK-biased differentiation from bone marrow CD34
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.